Prot #CA209-77T: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resec

Project: Research project

Project Details

StatusActive
Effective start/end date8/6/20 → 8/6/26

Funding

  • Bristol-Myers Squibb Company ((OE) Prot #CA209-77T)